drugset / Trial / NCT01472796

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension

NCT01472796

Phase 4 Unknown 92 enrolled Wayne State University Novartis · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

In this research study, the goal is to find out if a currently FDA-approved medication called Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure and improve heart function in the African American population. High blood pressure occurs earlier in life in African Americans, is more severe, and is associated with greater organ damage in relation to uncontrolled hypertension. Having low levels of Vitamin D is also very common in the African American population. Research has shown that there may be a link between low Vitamin D levels and the ability of high blood pressure medications to be fully effective.

Timeline

Start
2011-07
Primary completion
2013-07
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aliskiren Small molecule 300 mg

Indications